教育经历

2004-2008  厦门大学生物系生命科学专业，学士  

2008-2010  武汉大学生命科学学院细胞生物学，硕士

2010-2013  武汉大学生命科学学院细胞生物学，博士

工作经历与任职

2013-2017 美国北卡罗来纳大学教堂山分校，博士后

2017-2019 美国北卡罗来纳大学教堂山分校，研究助理教授

2019-   武汉大学，教授

获奖情况

2012 国家研究生奖学金

2013 武汉大学研究生学术创新奖

2015 UCRF Pilot Award

2016 DoD Breast Cancer Research Program Breakthrough Fellowship

研究领域

   本课题组主要从事肿瘤代谢、炎症和细胞信号转导的基础研究。运用细胞和动物模型、分子生化实验、代谢组学、转录组学以及临床样本等手段阐述肿瘤发生发展的分子机制，为肿瘤治疗提供新线索。

   乳腺癌是女性最常见的恶性肿瘤之一，70%左右的乳腺癌表达雌激素受体。尽管靶向雌激素受体的药物（如Tamoxifen）其疗效得到广泛认可，但仍有大比例雌激素受体阳性乳腺癌对内分泌治疗显示出固有耐药和获得性耐药；肾透明细胞癌是泌尿系统中发病率最高的恶性肿瘤之一，抑癌基因VHL的失活存在于高达90%左右的肾透明细胞癌中，因此，剖析VHL失活效应对治疗此病尤其关键。本实验室基于前期分别以雌激素受体阳性乳腺癌（Zhang et. al, 2015, EMBO J）与肾透明细胞癌（Zhang et. al, 2018, Science）为模型的科研成果展开工作。

代表性论文

1. Zhang J*, Wu T*, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG Jr, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018 Jul 20;361(6399):290-295. doi:10.1126/science. aap8411. PubMed PMID: 30026228.

• Highlighted by Sanchez DJ and Simon MC. Transcriptional control of kidney      cancer. Science 2018 Jul      20; 361 (6399): 226-227. DOI: 10.1126/science.aau4385

• Commentary: ZHX2 is an oncogenic driver of kidney cancer. Cancer Discovery 2018 Jul 27      DOI: 10.1158/2159-8290.CD-RW2018-125

• Faculty1000      (Exceptional)

2. Zhang J#, Zhang Q#. VHL and Hypoxia Signaling: Beyond HIF in Cancer. Biomedicines. 2018 Mar 19;6(1). pii: E35. doi: 10.3390/biomedicines6010035. Review. PubMed PMID: 29562667; PubMed Central PMCID: PMC5874692.

3. Zhang J#, Zhang Q#. Using Seahorse Machine to Measure OCR and ECAR in Cancer Cells. Methods Mol Biol. 2019;1928:353-363. doi: 10.1007/978-1-4939-9027-6_18. PubMed PMID: 30725464. (*: equal contribution)

4. Zhang J*, Wang C*, Chen X, Takada M, Fan C, Zheng X, Wen H, Liu Y, Wang CG, Pestell RG, Kaelin WG Jr, Liu XS and Zhang Q (2015). EglN2 Associates with NRF-PGC1α Complex and Controls Mitochondrial Function in Breast Cancer. EMBO J, 2015 Dec 2; 34(23): 2953-70,

5. Zhang J, Zheng X and Zhang Q. EglN2 positively regulates mitochondrial function in breast cancer. Mol Cell Oncol, 2015 Dec 22;3(2):e1120845. doi: 10.1080/23723556.2015.1120845. eCollection 2016 Mar. PubMed PMC4905419.

6. Zhang J, Hu MM, Shu HB, Li S. Death-associated protein kinase 1 is an IRF3/7-interacting protein that is involved in the cellular antiviral immune response. Cell Mol Immunol. 2014 May;11(3):245-52. PubMed PMID: 24531619; PubMed Central PMCID: PMC4085485.

7. Zhang J, Hu MM, Wang YY, Shu HB. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J Biol Chem. 2012 Aug 17;287(34):28646-55. PubMed PMID: 22745133; PubMed Central PMCID: PMC3436586.

8. Ran Y, Zhang J, Liu LL, Pan ZY, Nie Y, Zhang HY, Wang YY. Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate antiviral immune response. J Mol Cell Biol. 2016 Feb;8(1):31-43. PubMed PMID: 26611359.

9. Hu MM, Yang Q, Zhang J, Liu SM, Zhang Y, Lin H, Huang ZF, Wang YY, Zhang XD, Zhong B, Shu HB. TRIM38 inhibits TNFα- and IL-1β-triggered NF-κB activation by mediating lysosome-dependent degradation of TAB2/3. Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1509-14. PubMed PMID: 24434549; PubMed Central PMCID: PMC3910612.

10. Chen H, Li Y, Zhang J, Ran Y, Wei J, Yang Y, Shu HB. RAVER1 is a coactivator of MDA5-mediated cellular antiviral response. J Mol Cell Biol. 2013 Apr;5(2):111-9. PubMed PMID: 23390309.

11.  Lei CQ, Zhong B, Zhang Y, Zhang J, Wang S, Shu HB. Glycogen synthase kinase 3β regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity. 2010 Dec 14;33(6):878-89. PubMed PMID: 21145761.

课题组积极招收学生和博士后加入！